Video-oculography and Parkinson's Disease: A Prospective Study
This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015): * the evolution of oculomotricity markers over time. * the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years. * the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography. * the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.
• Male or Female;
• Clinically defined idiopathic Parkinson's Disease (PD);
• Brain MRI performed in routine care in the 12 months preceding inclusion;
• Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;
• Hoehn \& Yahr score: 1 to 3;
• Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);
• Neuro-cognitive disorders: absent or minor (according to DSM5);
• Sufficient written and oral expression in French;
• Covered by a health insurance system;
⁃ Written informed consent signed by the patient;
⁃ Presence of a caregiver.